Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 28, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - April 28, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/21/17 - Global Big Pharma Partnering Terms and Agreements Rising by Demand for Better Health Care, Critical Deals During 2010-2017
The right pharma partnership can provide a truly practical and unbiased evaluation in a highly profitable environment. The study will certainly enrich pharma businesses by covering the current situation and the growth of the big pharma partnering deals. The evaluation dissects and finds useful market trends, deals and strategies during the period f
4/21/17 - VOCSN By Ventec Life Systems Receives FDA 510(k) Clearance
Bothell, Wash-based Ventec Life Systems has received 510(k) clearance from the FDA for its VOCSN portable respiratory device for patients on a ventilator.
4/20/17 - 2017 Recent FDA-Approved Therapeutics
Dublin- Research and Markets has announced the addition of the "Recent FDA-approved Therapeutics" report to their offering. This Genetic Technology TOE profiles therapeutics that have been recently approved by FDA. -First FDA Approved Immunotherapy for Metastatic Merkel Cell Carcinoma- Relapsing Multiple Sclerosis Now Has a Novel FDA-approved Drug
4/20/17 - 2017 Recent FDA-Approved Therapeutics - Research and Markets
Research and Markets has announced the addition of the "Recent FDA- approved Therapeutics" report to their offering. This Genetic Technology TOE profiles therapeutics that have been recently approved by FDA. Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Fre
4/20/17 - AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with...
By a News Reporter-Staff News Editor at Women's Health Weekly- AbbVie, a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc., announced detailed results from a Phase 2 b clinical trial evaluating the efficacy and safety of elagolix alone or in combination with add-back therapy compared to placebo. The data demonstrat
4/20/17 - Abeona to Present At Multiple Upcoming Conferences
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, today announced President and CEO, Timothy J. Miller, PhD, will present at the Gene Therapy for Rare Disorders 2017 and the Alliance of Regenerative Medicine 5 th Annual Cell and Gene
4/20/17 - Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today that it intends to offer to sell shares of its common stock in an underwritten public offering. Raymond James& Associates, Inc. will act as the so
4/20/17 - Adverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors
From 2002 to 2010, Dr. Spivey worked with Meda AB after the acquisition of MedPointe Pharmaceuticals, serving as chief scientific officer and head of research and development for both. Earlier in his career, Dr. Spivey worked for Pharmacia Corporation, Schering-Plough Corporation, Parke-Davis/Warner-Lambert, and Boots Pharmaceuticals, Inc..
4/20/17 - Agency wants faster research on non-addictive painkillers as drug abuse grows [Lexington Herald-Leader]
Right now, the nation is short on safe, effective alternatives to addictive pain drugs called opioids, said Collins, who heads NIH. Collins said the NIH is working with the U.S. Food and Drug Administration and the pharmaceutical industry to find ways to speed up development of non-addictive alternatives to opioids, and to find ways to provide more
4/20/17 - AGTC to Present at the 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017
Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Alliance for Regenerative Medicine s 5 th Annual Cell& Gene Therapy In
4/20/17 - Alder BioPharmaceuticals to Host Conference Call to Discuss First Quarter 2017 Financial and Operating Results
Alder BioPharmaceuticals , Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its first quarter 2017 financial and operating results after the close of U.S. financial markets on Thursday, April 27, 2017. Alder BioPharmaceuticals, Inc., is a clinical-stage...
4/20/17 - Aldeyra Gets Orphan Drug Designation for ADX-102
Aldeyra Therapeutics received an orphan drug designation by the US Food and Drug Administration for ADX-102 in treating the rare disease Sjgren-Larsson Syndrome. The skin disease associated with SLS is physically and emotionally debilitating, leading to considerable social stigma and requiring significant daily care and medical resources, s
4/20/17 - Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjgren-Larsson Syndrome
Aldeyra Therapeutics, Inc., a clinical-stage biotech company devoted to treating diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules, today announced that the United States Food and Drug Administration has granted Aldeyra's novel compound ADX-102 orphan drug designation for the
4/20/17 - Allergan Announces 13 Presentations on Chronic Migraine, Upper and Lower Limb Spasticity, Cervical Dystonia and Alzheimer's Disease at the American Academy of Neurology Meeting in Boston
Allergan plc, a leading global pharmaceutical company today announced that it has 13 presentations at the upcoming 69th American Academy of Neurology annual meeting taking place April 22-28, 2017 in Boston. "Epidemiology of Migraine in Men: Results from the Chronic Migraine Epidemiology and Outcomes Study" Program Speaker: Ann Scher, PhD PL8, In
4/20/17 - Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY romosozumab
By a News Reporter-Staff News Editor at Women's Health Weekly- Amgen and UCB announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY?*, an investigational agent for postmenopausal women with osteoporosis. The results were presented in an oral session at ENDO 2017, th
4/20/17 - Arsanis Announces Initial Clinical Data for ASN100 to be Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
WALTHAM, Mass.& VIENNA Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post-infection treatment of serious infectious diseases, today announced that the company will be reporting data in five poster presentations at the 27th European Congress of Clinical Microbiology and...
4/20/17 - Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017
Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced that its collaborating investigators at the Queensland Institute of Medical Research and The University of Queensland are reporting...
4/20/17 - Atossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1 Endoxifen Dose Escalation Study
Atossa Genetics, Inc., a clinical-stage pharmaceutical company, today announced that it has received a positive interim review on its Phase 1 study of endoxifen, which is an active metabolite of the FDA approved drug tamoxifen, which is indicated for breast cancer and breast cancer prevention in high risk patients. The study is being conducted on b
4/20/17 - Aurinia Releases Additional 48-Week Data from the AURA-LV Study During Late-Breaking Session at the National Kidney Foundation 2017 Spring Clinical Meetings
Aurinia Pharmaceuticals Inc. a clinical stage biopharmaceutical company focused on the global immunology market, today announced additional 48- week results from its global Phase IIb AURA-LV study in lupus nephritis during the National Kidney Foundation 2017 Spring Clinical Meetings in Orlando, FL. In addition to the trial meeting its complete and.
4/20/17 - Avantor Acquires Puritan Products
Avantor Performance Materials, LLC, announced today the acquisition of Puritan Products, Inc., a supplier of cGMP buffers and solutions for Biopharma customers, and high-purity chemistries for Research and Electronic Materials customers. Avantor is a global supplier of ultra-high-purity materials for the life sciences and advanced technology...
4/20/17 - Bavarian Nordic Announces Initiation of Phase 2 Combination Trial of PROSTVAC, Ipilimumab and Nivolumab in Patients with Localized Prostate Cancer [Sudan Tribune]
-Second trial investigating PROSTVAC in combination with checkpoint inhibitors from Bristol-Myers Squibb. COPENHAGEN, Denmark, April 19, 2017- Bavarian Nordic A/S today announced the initiation of a Phase 2 clinical trial of its prostate cancer immunotherapy candidate, PROSTVAC, in combination treatment with YERVOY and/or OPDIVO, both of which are
4/20/17 - Bicycle Therapeutics Announces a Candidate Preclinical Milestone in Its Ophthalmology Alliance with ThromboGenics
CAMBRIDGE, England& CAMBRIDGE, Mass. Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, today announced the receipt of a preclinical milestone in connection with the advancement of a Bicycle into preclinical development for the treatment of diabetic ma
4/20/17 - BioPharmX Completes Last Subject Visit in its Phase 2b Trial of BPX-01, Expects to Report Topline Results First Half of May 2017
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, announced the last subject visit in its Phase 2 b trial was on March 24, 2017 and the last investigational site close-out visit was April 7, 2017. BioPharmX Corporation is a Silicon Valley- based specialty pharmaceutical company that seeks to
4/20/17 - Biotech Stocks Under Scanner Biostage, Keryx Biopharma, Kite Pharma, and ZIOPHARM Oncology
Under evaluation this morning are: Biostage Inc., Keryx Biopharmaceuticals Inc., Kite Pharma Inc., and ZIOPHARM Oncology Inc.. Shares in Holliston, Massachusetts headquartered Biostage Inc. jumped 3.42%, ending Wednesday's trading session at $0.31. On April 18 th, 2017, Biostage announced that it has appointed Stephen F. Badylak DVM, PhD, MD to its
4/20/17 - Blog Coverage CytRx Announces FDA's Approval for New Drug Application
LONDON, UK/ ACCESSWIRE/ April 20, 2017/ Active Wall St. blog coverage looks at the headline from CytRx Corp. as the Company announced on April 19, 2017, that the US Food and Drug Administration has agreed to a rolling submission for a New Drug Application submission for the Company's aldoxorubicin drug for the treatment of soft tissue sarcomas.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415